The company posted adjusted of $0.11 per share, up 57% year-over-year, with the figure exceeding analysts’ expectations of $0.09 per share.
The company remains focused on acquiring or in-licensing innovative, technology platforms and early stage programs in therapeutic areas different from neuromuscular diseases. (smarteranalyst.com)
CPRX it`s an easy 50% in my opinion.
$40 Million Share Repurchase.
Market Cap 453.715M.
PE Ratio ( TTM ) 6.15.
75mil revenue, 119mil in 2020
haven`t seen such a great on a penny stock.
now trading at 4,94usd.
3/18/2021 Roth Capital Boost Price Target Buy $6.50 ➝ $7.00
H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on the stock with a price target of $9
If you are also interested to test some amazing BUY and SELL INDICATORS that i use, which give the signal at the beginning of the candle, not at the end of it, just leave me a message.
How to install the indicators: https://www.youtube.com/watch?v=VsJ3V3Uczsk&t=2s&ab_channel=TradingIndicators
My Best Stock Picks: https://www.patreon.com/tradingindicators